Emerging drugs for atopic dermatitis

被引:22
作者
Ong, Peck Y. [1 ]
机构
[1] Univ So Calif, Childrens Hosp Los Angeles, Dept Pediat, Keck Sch Med,Div Clin Immunol & Allergy, Los Angeles, CA 90027 USA
关键词
atopic dermatitis; defensin; experimental therapy; filaggrin; INHIBITOR IMPROVES DERMATITIS; ANTI-CD20 RITUXIMAB TREATMENT; PIMECROLIMUS CREAM 1-PERCENT; SILVER-COATED TEXTILES; HUMAN EPITHELIAL-CELLS; HOUSE-DUST MITE; DOUBLE-BLIND; LYMPHOCYTE FUNCTION; CONTROLLED-TRIAL; TACROLIMUS OINTMENT;
D O I
10.1517/14728210902721248
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, affecting 10 - 20% of children and 2% of adults worldwide. Preventive treatment of AD consists of daily skin hydration and emollient therapy; but the majority of patients still require symptomatic treatment with topical corticosteroids and/or topical calcineurin inhibitors, both of which may be associated with potential long-term side effects. With increasing evidence supporting the role of skin barrier defects in the pathogenesis of AD, there is also a parallel increase in medications that claim to assist barrier repair. The current review discusses some exciting results with these medications, as well as the challenges that lie ahead of them. While barrier repair treatments offer some promise, there continues to be a need for safer anti-inflammatory medications. Some of these medications under investigation are phosphodiesterase-4 inhibitors, urocanic acid oxidation products and IL-4/IL-13 receptor blockers. The review also discusses anti-staphylococcal treatments including nanocrystalline silver cream, silver- and antimicrobial-coated fabrics, and anti-itch treatments including mu-opiod receptor antagonists, chymase inhibitors and cannabinoid receptor agonists. These medications may become an integral part of AD therapy.
引用
收藏
页码:165 / 179
页数:15
相关论文
共 116 条
[1]  
Abramovits William, 2006, Skinmed, V5, P29
[2]  
Abramovits William, 2006, J Drugs Dermatol, V5, P236
[3]   Thymic stfomal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells [J].
Allakhverdi, Zoulfia ;
Comeau, Michael R. ;
Jessup, Heidi K. ;
Yoon, Bo-Rin Park ;
Brewer, Avery ;
Chartier, Suzanne ;
Paquette, Nicole ;
Ziegler, Steven F. ;
Sarfati, Marika ;
Delespesse, Guy .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (02) :253-258
[4]   Contact dermatitis to pentylene glycol in a prescription cream for atopic dermatitis: Case report [J].
Amado, Antoine ;
Taylor, James S. ;
Murray, Debora A. ;
Reynolds, Jeffrey S. .
ARCHIVES OF DERMATOLOGY, 2008, 144 (06) :810-812
[5]   Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis [J].
Badertscher, K ;
Brönnimann, M ;
Karlen, S ;
Braathen, LR ;
Yawalkar, N .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2005, 296 (10) :503-506
[6]   A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis [J].
Behshad, Ramona ;
Cooper, Kevin D. ;
Korman, Neil J. .
ARCHIVES OF DERMATOLOGY, 2008, 144 (01) :84-88
[7]  
Belloni G, 2005, EUR J DERMATOL, V15, P31
[8]   Predictors of atopic dermatitis severity over time [J].
Ben-Gashir, MA ;
Seed, PT ;
Hay, RJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) :349-356
[9]   Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids [J].
Bewley, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (05) :917-920
[10]   Phototherapy in the management of atopic dermatitis: a systematic review [J].
Bhavani Meduri, N. ;
Vandergriff, Travis ;
Rasmussen, Heather ;
Jacobe, Heidi .
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2007, 23 (04) :106-112